Changes of humoral and secretory defending factors against immunotherapy of children being frequently ill

Abstract

Clinical and immunological efficiency of immunotherapy with thymus and bone marrow peptides, Ribomunyl, IRS 19 and their combination was assessed in 370 children being frequently ill in the near (12 months) and remote periods. In contradistinction to the thymus and bone marrow peptides a long-term positive influence of Ribomunyl alone and in combination with IRS 19 on the synthesis of lgA, SlgA and saliva lyzosime was shown, especially in the children with recurrent respiratory infections. A necessity of the immunologic monitoring in children frequently being ill was marked not only for systemic immunity but also for local (mucous) one.